Melinda Engevik, PhD

Personal Statement

Dr. Engevik’s research focuses on the interaction between the gut microbiota and the intestinal mucus layer. Her interests include both mucosa-associated pathogens and commensal microbes, with the goal of delineating how microbes manipulate mucins and glycans to promote colonization. 

Education

Organizations

,

,

,

,

* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.

Engevik MA, Versalovic J. Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology. Microbiology Spectrum 2017;5(5).

Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR, Worrell RT. Human Clostridium difficile infection: altered mucus production and composition. American Journal of Physiology-Gastrointestinal and Liver Physiology 2015;308(6):G510-24.

Engevik MA, Engevik KA, Yacyshyn MB, Wang J, Hassett DJ, Darien B, Yacyshyn BR, Worrell RT. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. American Journal of Physiology-Gastrointestinal and Liver Physiology 2015;308(6):G497-509. 

Engevik MA, Hickerson A, Shull GE, Worrell RT. Acidic conditions in the NHE2(-/-) mouse intestine result in an altered mucosa-associated bacterial population with changes in mucus oligosaccharides. Cellular Physiology and Biochemistry 2013;32(7):111-28. 

Engevik MA, Aihara E, Montrose MH, Shull GE, Hassett DJ, Worrell RT. Loss of NHE3 alters gut microbiota composition and influences Bacteroides thetaiotaomicron growth. American Journal of Physiology-Gastrointestinal and Liver Physiology 2013;305(10):G697-711. 

View All Publications:

https://www.ncbi.nlm.nih.gov/pubmed?term=Engevik%2C%20Melinda%5BAuthor%…;